Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biotene OralBalance is a moisturizing oral gel designed to provide long-lasting relief from dry mouth (xerostomia). Originally developed by Laclede and currently marketed by GSK, the gel is formulated to mimic the lubricating and protective properties of natural saliva. It primarily contains humectants such as glycerin and xylitol, which help maintain moisture on the oral mucosa. Beyond its common use for xerostomia, Biotene OralBalance has been studied in clinical trials—specifically in neonatal intensive care units—as part of an oral care regimen to prevent ventilator-associated pneumonia (VAP). The hypothesis is that maintaining oral hydration and hygiene reduces the colonization of pathogenic bacteria in the oropharynx, thereby decreasing the risk of lung infection during mechanical ventilation. The product is typically regulated as a medical device in several jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biotene OralBalance (Laclede).